CJC-1295 + Ipamorelin: The Growth Hormone Stack — Clinical Evidence, Dosing & What to Expect
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
The CJC-1295 and Ipamorelin combination is the most widely prescribed growth hormone peptide stack in anti-aging and regenerative medicine clinics. By combining a long-acting GHRH analog with a selective growth hormone secretagogue, this stack produces sustained, physiological elevations in GH and IGF-1 without the side effects of exogenous growth hormone.
What Are CJC-1295 and Ipamorelin?
CJC-1295: The Long-Acting GHRH Analog
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids. CJC-1295 with Drug Affinity Complex (DAC) binds to serum albumin, extending its half-life to approximately 6-8 days.
Teichman et al. (2006) demonstrated that subcutaneous CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults Teichman et al., 2006.
Ipamorelin: The Selective Growth Hormone Secretagogue
Ipamorelin is a pentapeptide that activates the growth hormone secretagogue receptor (GHSR). Raun et al. (1998) established it as a potent and selective GH secretagogue that did not release ACTH or cortisol significantly Raun et al., 1998.
The Synergy: Why Combine Them?
Yin et al. (2014) highlighted the synergistic effect when GHRH and GHSR agonists are co-administered Yin et al., 2014.
CJC-1295 acts as the “amplifier” — increasing somatotroph capacity via cAMP/PKA signaling.
Ipamorelin acts as the “trigger” — providing pulsatile GH release via PLC/IP3/DAG pathway.
Together, they produce GH elevations 2-3x greater than either peptide alone.
Clinical Evidence
Growth Hormone and IGF-1 Elevation
A single dose of CJC-1295 produced a 2-10 fold GH increase sustained for up to 6 days, with IGF-1 elevated for 9-11 days Teichman et al., 2006.
Safety Profile
Sigalos and Pastuszak (2018) highlighted that GH secretagogues show promise but need more long-term studies Sigalos & Pastuszak, 2018. A 2026 review noted limited evidence for clinical use in humans Mayfield et al., 2026.
---
> Considering adding this to your protocol? Work with licensed providers who understand peptide therapy. Telegenix offers personalized protocols based on your bloodwork and goals. Schedule your free consultation today.
---
CJC-1295 + Ipamorelin vs. Other GH Therapies
| Feature | CJC-1295 + Ipamorelin | HGH (Somatropin) | MK-677 | Sermorelin |
|---|---|---|---|---|
| Mechanism | Dual GHRH + GHSR | Direct GH replacement | Oral GHSR agonist | GHRH analog |
| GH Pattern | Pulsatile (physiological) | Flat (supraphysiological) | Sustained | Pulsatile |
| IGF-1 Increase | 1.5-3x baseline | 2-5x baseline | 1.5-2x baseline | 1.2-2x baseline |
| Cortisol Impact | Minimal | None | Mild increase | None |
| Feedback Suppression | No | Yes | Minimal | No |
Dosing Protocols
| Protocol | CJC-1295 Dose | Ipamorelin Dose | Frequency | Duration |
|---|---|---|---|---|
| Anti-Aging | 100 mcg | 200 mcg | Once daily (before bed) | 12-16 weeks |
| Body Composition | 100 mcg | 300 mcg | 1-2x daily | 12-16 weeks |
| Recovery | 100 mcg | 200-300 mcg | 2x daily | 8-12 weeks |
| CJC-1295 DAC | 2 mg weekly | 200 mcg daily | See notes | 12-16 weeks |
Timing: Best on an empty stomach before bed. Avoid eating for 30-60 minutes after injection, as insulin blunts GH release.
What to Expect: Timeline
| Timeframe | Expected Effects |
|---|---|
| Week 1-2 | Improved sleep quality, vivid dreams |
| Week 3-4 | Increased energy, faster recovery |
| Week 6-8 | Skin quality improvements, body composition changes begin |
| Week 10-12 | Measurable fat loss, lean mass gains, improved IGF-1 on bloodwork |
| Week 12-16 | Full benefits realized; reassess with bloodwork |
---
> Ready to start a personalized peptide protocol? The licensed providers at Telegenix specialize in peptide therapy and hormone optimization. Book a free consultation to get a protocol tailored to your bloodwork, goals, and biology.
---
Key Takeaways
The CJC-1295 + Ipamorelin stack represents the current gold standard in peptide-based growth hormone optimization. The clinical evidence supports its safety and efficacy for GH and IGF-1 elevation, though long-term human data remains limited.
> Related Comparison: Tesamorelin vs Ipamorelin: GH Peptide Comparison
> Related Comparison: NAD+ vs NMN: Which Longevity Supplement?
> Related Comparison: Sermorelin vs CJC-1295: Complete Comparison
References
---
Explore Related Peptides on OnlinePeptideDoctor.com
Disclaimer: This article is for educational and informational purposes only. It is not medical advice. CJC-1295 and Ipamorelin are research peptides not FDA-approved for clinical use.
---
Related Reading
Explore more in-depth guides on related topics:
For a comprehensive overview, see our Complete Guide to Peptide Therapy.
---